Effects of Lung Volume on Upper Airway Patency During Drug Induced Sleep Endoscopy
Launched by EMORY UNIVERSITY · Apr 22, 2022
Trial Information
Current as of November 04, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how the amount of air in the lungs affects the throat's ability to stay open during sleep, especially for people with obstructive sleep apnea (OSA). OSA is a condition where a person's breathing repeatedly stops and starts during sleep, often causing choking sensations. To better understand how lung volume impacts throat collapse, participants will undergo a procedure called drug-induced sleep endoscopy (DISE), which allows doctors to see the throat while the patient is lightly sedated. Participants will be divided into two groups: one will use a special ventilator to change lung volumes, and the other will receive gentle electrical stimulation to help the diaphragm work better.
To be eligible for this study, you need to be at least 18 years old, have a diagnosis of OSA, and be interested in surgical options for treatment. You also need to be able to give consent and have no major health issues that could affect surgery or anesthesia. During the study, you can expect to have the DISE procedure as part of your regular evaluation, along with lung function tests. This research aims to improve how doctors assess patients for surgery and could lead to new treatment options for those with OSA.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
 - • Adult patients (≥ 18 yrs) willing and capable of providing informed consent
 - • Obstructive sleep apnea (AHI ≥ 5 events/hour)
 - • Must be willing and able to provide informed consent to participate in the study.
 - • Interested in surgical treatments of OSA and have consented for a DISE procedure as part of their routine clinical evaluation.
 - • Patients are evaluated and cleared by anesthesia prior to the procedure.
 - Exclusion Criteria:
 - • No significant uncontrolled medical co-morbidities (e.g., uncontrolled hypertension, unstable angina, uncompensated heart failure or COPD).
 - • Any medical comorbidity that would prevent the patient from receiving anesthesia or having surgery
 - • Inability to tolerate negative pressure ventilator or perform PFT (i.e. claustrophobia)
 - • No incapacitating disability that interferes with execution of the protocol
 
About Emory University
Emory University, a leading research institution located in Atlanta, Georgia, is dedicated to advancing medical knowledge and improving patient care through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, Emory harnesses the expertise of its renowned faculty and state-of-the-art facilities to conduct cutting-edge research across various fields, including oncology, neurology, and infectious diseases. The university's commitment to ethical research practices and patient safety ensures that all clinical trials are designed to generate valuable data that can lead to significant therapeutic advancements. By fostering partnerships with local hospitals and community organizations, Emory strives to translate research findings into real-world applications, ultimately enhancing health outcomes for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Atlanta, Georgia, United States
Patients applied
Trial Officials
Jason Yu, MD
Principal Investigator
Emory University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials